Evidence map›Paper›PMID 34012371›Full record

ArticleBreast care (Basel, Switzerland)2021

Conditional Disease-Free and Overall Survival of 1,858 Young Women with Non-Metastatic Breast Cancer and with Participation in a Post-Therapeutic Rehab Programme according to Clinical Subtypes.

Jonathan Pruessmann, Telja Pursche, Friederike Hammersen, Alexander Katalinic, Dorothea Fischer, Annika Waldmann

Open access · bronzeAbstract read
In one paragraph

Article in Breast care (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Jonathan PruessmannInstitute for Social Medicine and Epidemiology, Lübeck University, Lübeck, Germany.
Telja PurscheDepartment of Gynaecology and Obstetrics, University Hospital Schleswig-Holstein, Lübeck, Germany.
Friederike HammersenInstitute for Social Medicine and Epidemiology, Lübeck University, Lübeck, Germany.
Alexander KatalinicInstitute for Social Medicine and Epidemiology, Lübeck University, Lübeck, Germany.
Dorothea FischerDepartment of Gynaecology and Obstetrics, Hospital Ernst von Bergmann, Potsdam, Germany.
Annika WaldmannInstitute for Social Medicine and Epidemiology, Lübeck University, Lübeck, Germany.
University of Lübeck · DEIndependent Centre for Privacy Protection · DEKlinikum Ernst von Bergmann · DEKrankenhaus Düren · DEUniversity Cancer Center Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer in young women is associated with unfavourable tumour biology and is the main cause of death in this group. Conditional survival analysis estimates survival rates under the pre-condition of already having survived a certain time.

objectivesTo describe conditional disease-free and overall survival of female breast cancer patients according to clinical subtypes and age.

methodsThis study analyses information from 1,858 breast cancer patients aged between 21 and 54 years, who were taking part in a post-therapeutic rehab programme (time between diagnosis and rehab start: maximum 24, median 11 months). Mean follow-up time was 3.6 years. We describe biological, clinical and pathological features in regard to different age groups (<40 and ≥40 years) and report conditional 5-year survival rates for overall and disease-free survival, and Cox proportional hazard models.

resultsVery young and young patients differed in regard to hormone receptor negativity, tumour grade, lymphovascular invasion, and molecular subtypes. Young women bore triple-negative and HER2-like disease more frequently. Conditional 5-year overall survival did not differ substantially between women <40 and 40-54 years of age (95 vs. 96%). It was highest for women with cancer of the luminal A subtype (98%) and lowest for the triple-negative subtype (91%). Lymphangiosis was a significant predictor of death. Results for disease-free survival were comparable.

conclusionsConditional 5-year overall survival after non-metastatic breast cancer was as high as 95.5%, and disease-free survival was 85.2%. When controlling for time between diagnosis and rehab start, molecular subtypes influenced overall and disease-free survival prospects. When additionally controlling for clinical characteristics, this effect only remained stable for disease-free survival.

Indexed as

Non-metastatic breast cancerSurvivalYoung adults

Identifiers

PMID34012371
PMCPMC8114044
OpenAlexW3025437479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.